Berfin Gülave
Promovendus
- Naam
- B. Gülave
- Telefoon
- +31 71 527 6071
- b.gulave@lacdr.leidenuniv.nl
Voor meer informatie zie de Engelstalige website.
Promovendus
- Wiskunde en Natuurwetenschappen
- Leiden Academic Centre for Drug Research
- LACDR/Pharmacology
- Saleh M.A.A.E.W., Gülave B., Campagne O., Stewart C.F., Elassaiss J. & Lange E.C.M. de (2023), Using the LeiCNS-PK3.0 physiologically-based pharmacokinetic model to predict brain extracellular fluid pharmacokinetics in mice, Pharmaceutical Research 40: 2555-2566.
- Gülave B., Budda D., Saleh M.A.A.E.W., Hasselt J.G.C. van & Lange E.C.M. de (2023), Does nonlinear blood-brain barrier transport matter for (lower) morphine dosing strategies?, European Journal of Pharmaceutical Sciences 187: 106482.
- Saleh M.A.A.E.W., Hirasawa M., Sun M., Berfin G., Elassaiss J. & Lange E.C.M. de (2022), The PBPK LeiCNS-PK3.0 framework predicts Nirmatrelvir (but not Remdesivir or Molnupiravir) to achieve effective concentrations against SARS-CoV-2 in human brain cells, European Journal of Pharmaceutical Sciences 181: 106345.
- Gülave B., Hew M.N., Groot J.S. de, Rodwell L., Teerenstra S. & Fabriek B.O. (2021), High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors, ESMO Open 6(3): 100107.
- Brink W.J. van den, Wong Y.C., Gülave B., Graaf P.H. van der & Lange E.C.M. de (2017), Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling, AAPS Journal 19(1): 274–285.
Geen relevante nevenwerkzaamheden